Camrelizumab, Apatinib, Temozolomide Combination Is Efficacious for Acral Melanoma

Source: Cancer Therapy Advisor, June 2022

A combination of camrelizumab with apatinib and temozolomide has good antitumor activity as first-line therapy in patients with advanced acral melanoma, according to research presented at the 2022 ASCO Annual Meeting.

The single-center, single-arm, phase 2 study ( Identifier: NCT04397770) assessed efficacy and safety of the 3-drug combination in patients aged 18 to 75 years with unresectable stage III or metastatic acral melanoma who had not received any systemic antitumor therapy in the advanced setting. This treatment strategy combines immunotherapy (camrelizumab), inhibition of vascular endothelial growth factor receptor 2 signaling (apatinib), and induction of apoptosis (temozolomide).

All patients on the study received camrelizumab (200 mg every 2 weeks), apatinib (250 mg once per day), and temozolomide (200 mg/m2 on days 1-5), until disease progression or intolerable toxicity. A cycle was considered to be 28 days.